{{Rsnum
|rsid=2020865
|Gene=FMO2
|Chromosome=1
|position=171207773
|Orientation=plus
|GMAF=0.1006
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=FMO2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 0.9 | 8.0 | 91.2
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 12.9 | 49.7 | 37.4
| ASW | 7.0 | 38.6 | 54.4
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 10.9 | 89.1
| LWK | 12.8 | 39.4 | 47.7
| MEX | 0.0 | 6.9 | 93.1
| MKK | 0.6 | 21.2 | 78.2
| TSI | 0.0 | 11.8 | 88.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2020865
|Name_s=g.22,060T>G, p.N413K
|Gene_s=
|Feature=
|Evidence=PubMed ID:15864117; PubMed ID:15922018; PubMed ID:18423897
|Annotation=The g.22,060G variant segregates with g.23,238C>T (with one exception). The allele containing both of these polymorphisms has been designated FMO2*2C.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161660840
}}

{{PMID Auto
|PMID=19420133
|Title=Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.
|OA=1
}}

{{GET Evidence
|gene=FMO2
|aa_change=Asn413Lys
|aa_change_short=N413K
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2020865
|overall_frequency_n=1402
|overall_frequency_d=10758
|overall_frequency=0.130322
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=16
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|nblosum100=1
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}